We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Does Statin Therapy Reduce Sympathoexcitation in Hypertension?

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00497016
Recruitment Status : Completed
First Posted : July 6, 2007
Last Update Posted : September 30, 2008
Information provided by:

Study Description
Brief Summary:
A number of patients with hypertension have increased central sympathetic activity. Statins seem to inhibit central sympathetic output. This study assesses the effect of statins on central sympathetic activity in hypertension patients.

Condition or disease Intervention/treatment
Hypertension Drug: atorvastatin 80 mg

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 13 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Official Title: Does Statin Therapy Reduce Sympathoexcitation in Hypertension?
Study Start Date : May 2007
Study Completion Date : March 2008

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions

Outcome Measures

Primary Outcome Measures :
  1. change in central sympathetic activity

Secondary Outcome Measures :
  1. change in cholesterol levels, renin and aldosteron

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • (Known) hypertension
  • stable drug therapy for at least 2 months
  • age 18-70 jaar
  • BMI 18-35 kg/m2
  • Sinusrhythm

Exclusion Criteria:

  • Recent cardiovascular event <6 mnd
  • Plasma Creatinin:
  • female: >120 mmol/L
  • male: >133 mmol/L
  • use of:
  • tricyclic antidepressants
  • alpha-1 -and/or alpha-2 blockers
  • disease of the autonomic nervous system (Parkinsons disease, Shy- Drager syndrome, etc)
  • Albuminuria >300 mg/dag
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00497016

Radboud University Medical Center Nijmegen
NIjmegen, Netherlands, 6500 HB
Sponsors and Collaborators
Radboud University
ZonMw: The Netherlands Organisation for Health Research and Development
Principal Investigator: Cees J Tack, MD, PhD Radboud University
More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00497016     History of Changes
Other Study ID Numbers: HTSTAT
First Posted: July 6, 2007    Key Record Dates
Last Update Posted: September 30, 2008
Last Verified: September 2008

Keywords provided by Radboud University:

Additional relevant MeSH terms:
Vascular Diseases
Cardiovascular Diseases
Atorvastatin Calcium
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Enzyme Inhibitors